High costs for diagnosis, care of nonalcoholic fatty liver disease

High costs for diagnosis, care of nonalcoholic fatty liver disease

(HealthDay)—The health care costs associated with nonalcoholic fatty liver disease (NAFLD) are considerable, especially at first diagnosis, according to a study published online May 18 in Hepatology.

Alina M. Allen, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues examined the total cost and resource utilization associated with a new NAFLD using U.S. medical and pharmacy claims data from OptumLabs Data Warehouse. A total of 152,064 adults with a first claim for NAFLD were identified, of whom 108,420 were matched to non-NAFLD contemporary controls in a 1:1 ratio. Participants were followed for a median of 2.6 years.

The researchers found that per NAFLD patient with private insurance, the total annual cost of care was $7,804 and $3,789 for a new diagnosis and for long-term management, respectively. These were significantly higher than the total annual costs per matched control with similar comorbidities ($2,298). The largest increases in health care utilization were represented by liver biopsies, imaging, and hospitalizations (relative risks, 55.0, 3.95, and 1.87, respectively), which may account for the increased costs in NAFLD versus controls.

"The costs associated with the care for NAFLD independent of its metabolic comorbidities are very high, especially at first diagnosis," the authors write. "Research efforts should focus on identification of underlying determinants of use, sources of excess cost, and development of cost-effective diagnostic tests."

More information: Abstract/Full Text (subscription or payment may be required)

Journal information: Hepatology

Copyright © 2018 HealthDay. All rights reserved.

Citation: High costs for diagnosis, care of nonalcoholic fatty liver disease (2018, June 11) retrieved 25 April 2024 from https://medicalxpress.com/news/2018-06-high-diagnosis-nonalcoholic-fatty-liver.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Germany: compensated cirrhosis substantially increases comorbidities and healthcare costs

1 shares

Feedback to editors